panitumumab,bevacizumab
roche,amgen,takeda
['colorectal', 'beva', 'vectibix', 'bevacizumab', 'panitumumab', 'rectal', '$amgn', 'amgen', 'takeda']
#amgen and takeda reported new head-to-head data show #vectibix (#panitumumab) demonstrated superior overall survival compared to #bevacizumab in combination with #chemotherapy in japanese patients with #wild type #ras #colorectalcancer #asco22 $amgn 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.